RTX (RTX) Q2 2025 Earnings Call July 22, 2025 08:30 AM ET Company ParticipantsChristopher Calio - Chairman & CEONeil Mitchill - CFONathan Ware - VP - Investor RelationsMyles Walton - Managing DirectorScott Deuschle - Director - Aerospace & Defense Equity ResearchSheila Kahyaoglu - Managing DirectorRonald Epstein - MD - Aerospace & DefenseSeth Seifman - Executive DirectorDouglas Harned - Managing DirectorGautam Khanna - Managing DirectorDavid Strauss - Managing Director - Aerospace & Defense Equity ResearchS ...

ISM3412是一款高口服生物利用度、高选择性的强效MAT2A（甲硫氨酸腺苷转移酶2A）抑制剂，其研 发流程由英矽智能自有生成化学平台Chemistry42赋能。该候选药物通过抑制MAT2A，降低S-腺苷甲硫 氨酸（SAM）这一细胞功能必需成分的水平，进而针对性杀伤MTAP缺失的癌细胞，同时保护健康细 胞。考虑到MTAP缺失突变广泛存在于非小细胞肺癌（NSCLC）、胰腺癌、膀胱癌等多种实体瘤，该策 略有望提供创新治疗方案。 该项I期临床研究分为剂量递增试验和剂量选择优化两大部分，受试者将每日一次接受ISM3412口服治 疗。除针对ISM3412的安全性、耐受性、药代动力学/药效动力学特性和初步抗肿瘤疗效评估外，此项 研究还将确定后续研究的推荐剂量。截至目前，该试验已在中国组长单位，即中国医学科学院肿瘤医院 完成了首例受试者入组和第一剂量队列的剂量限制性毒性（DLT）观察。 通过整合先进的AI和自动化技术，英矽智能在实际应用案例中展现出效率提升，为AI驱动的药物研发 树立了标杆。与传统药物研发通常需要2.5-4年的时间周期相比，英矽智能在2021至2024年间的自研项 目，从立项到提名临床前候选药物（PCC）的 ...

Core Viewpoint - The 27th "L'Oréal-UNESCO For Women in Science Awards" recognized five scientists for their groundbreaking research in natural sciences, mathematics, and computer science, with Chinese Academy of Sciences academician Wang Xiaoyun being one of the awardees, marking her as the ninth Chinese scientist to receive this honor [3][6]. Group 1: Achievements in Cryptography - Wang Xiaoyun's significant contributions to cryptography include revealing fundamental vulnerabilities in widely used hash functions, which has led to the establishment of new generation hash function standards widely applied in banking, computer security, and e-commerce [3][5]. - Her research on cryptographic algorithms, particularly the attacks on MD5 and SHA-1, has had a profound impact on global cryptography standards, prompting the development of new secure algorithms [4][5]. Group 2: Commitment to National Interests - Wang Xiaoyun emphasizes that her work in cryptography serves national interests, prioritizing the development of domestic cryptographic standards over participating in international design efforts [5]. - She played a crucial role in designing the SM3 hash function standard, which has been widely adopted in critical sectors such as finance and national security [5]. Group 3: Advocacy for Women in Science - The award aims to bridge the gender gap in science and enhance the visibility and influence of female researchers, with Wang Xiaoyun advocating for a supportive environment for young female scientists [6][8]. - The recognition of female scientists, including Wang Xiaoyun, reflects the growing strength of women in research, with nine Chinese female scientists having received this award to date [7][8].

作者：Cage 上世纪 50 年代信息论和 DNA 双螺旋的发现，点亮了生命科学与数字互联网这两个最关键的科技树；今天 AI for Science 开始将这两股洪流汇聚并指数级 加速。 大模型对生物系统这样复杂、非线性的系统有着前所未有的理解和生成能力，有望成为加速科学发现的关键引擎。 • Biology Foundation Model： 深挖单点大模型极限，AlphaFold 3 级别的里程碑是个开始； • AI Scientist： 将多智能体编排成实验操作系统，让科研流程变成可复制的 AI Agent； • AI-Native Therapeutics： 基于全栈 AI 平台押注复杂疗法，争夺下一个百亿美元药物； • AI-empowered solution： 通过独特数据与算法解决行业痛点，带来立竿见影的效率红利。 目录 01 Background 02 研究框架 03 Tech × Specialist：Biology foundation model 的范式变化 04 Tech × Biologist：自动化科研（AI Scientist）重塑研发流程 05 Bio x Generalist ...

英矽智能（InSilicoMedicine）日前向港交所递交上市申请，拟在香港联交所主板挂牌上市。作为全球领 先的AI驱动生物科技公司，英矽智能已通过自主开发的生成式人工智能平台Pharma.AI产生超20项临床 或IND阶段的资产。 AI赋能药物研发效率显著提升 英矽智能成立于2014年，是一家专注于AI驱动药物研发的生物科技公司。公司自主研发的生成式人工 智能平台Pharma.AI由Biology42、Chemistry42、Medicine42和Science42四大模块组成，可提供从新靶点 识别到小分子生成及临床结果预测的端对端服务。 凭借AI技术优势，英矽智能显著提升了药物研发效率。以新型TNIK靶点为例，从发现到首次人体临床 试验仅用时18个月，远低于传统方法平均4.5年的研发周期。 目前公司已有多个候选药物进入临床阶段。其中，ISM001-055已完成中国IIa期临床试验并获得FDA孤 儿药资格认定；ISM3091已在美国启动Ia期临床试验；ISM8207正与复星医药联合开发；ISM5043已授 权给Stemline；ISM5411已完成澳洲I期临床试验。 三项重大授权交易合约总值超20亿美元 ...